Cargando…

Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay

Cardiac troponin I (cTnI) is considered the gold standard biomarker for myocardial injury and shows a high degree of homology between humans and dogs. The ADVIA Centaur XP High-Sensitivity Troponin I (AC-cTnI-HS) assay has been validated for use in humans but not dogs. The study objectives were to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wesselowski, Sonya, Lidbury, Jonathan, Saunders, Ashley B., Gordon, Sonya G., Suchodolski, Jan S., Steiner, Joerg M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353792/
https://www.ncbi.nlm.nih.gov/pubmed/37463140
http://dx.doi.org/10.1371/journal.pone.0288801
_version_ 1785074779793915904
author Wesselowski, Sonya
Lidbury, Jonathan
Saunders, Ashley B.
Gordon, Sonya G.
Suchodolski, Jan S.
Steiner, Joerg M.
author_facet Wesselowski, Sonya
Lidbury, Jonathan
Saunders, Ashley B.
Gordon, Sonya G.
Suchodolski, Jan S.
Steiner, Joerg M.
author_sort Wesselowski, Sonya
collection PubMed
description Cardiac troponin I (cTnI) is considered the gold standard biomarker for myocardial injury and shows a high degree of homology between humans and dogs. The ADVIA Centaur XP High-Sensitivity Troponin I (AC-cTnI-HS) assay has been validated for use in humans but not dogs. The study objectives were to analytically validate the AC-cTnI-HS assay in dogs, to assess correlation between the AC-cTnI-HS and a previous ADVIA Centaur TnI-Ultra (AC-cTnI-U) assay, to assess cTnI sample storage stability, and to clinically evaluate the AC-cTnI-HS assay in healthy dogs and dogs with cardiac disease. Canine serum samples were used for analytical validation. Intra- and inter-assay variability, dilutional parallelism, and spiking recovery were assessed. Samples from 196 client-owned dogs were evaluated (healthy dogs (n = 39) or dogs with congenital heart disease (n = 54), myxomatous mitral valve disease (n = 68), dilated cardiomyopathy (n = 15), or myocarditis (n = 20)). Inter- and intra-assay coefficient of variation (%CV) was between 2.8–41.4% and 3.8–30.2%, respectively, with pools with concentrations >20 pg/mL all having %CVs <10%. The observed to expected ratios for dilutional parallelism and spiking recovery experiments ranged between 92.3 and 266.7.0% and 84.3 and 108%, respectively. A strong correlation between the AC-cTnI-HS and AC-cTnI-U assays was observed (Spearman’s ρ = 0.927), though a proportional bias existed, with AC-cTnI-HS assay concentrations being proportionally lower than AC-cTnI-U assay concentrations. Serum samples stored at -80°C had stable cTnI measurements for up to 2.7 years and after a single freeze-thaw cycle. Healthy dogs and dogs with congenital heart disease had significantly lower cTnI concentrations than dogs in the other three groups. The AC-cTnI-HS assay precisely, reproducibly, and accurately measures cTnI concentrations in dog serum with cTnI concentrations >20 pg/mL.
format Online
Article
Text
id pubmed-10353792
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-103537922023-07-19 Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay Wesselowski, Sonya Lidbury, Jonathan Saunders, Ashley B. Gordon, Sonya G. Suchodolski, Jan S. Steiner, Joerg M. PLoS One Research Article Cardiac troponin I (cTnI) is considered the gold standard biomarker for myocardial injury and shows a high degree of homology between humans and dogs. The ADVIA Centaur XP High-Sensitivity Troponin I (AC-cTnI-HS) assay has been validated for use in humans but not dogs. The study objectives were to analytically validate the AC-cTnI-HS assay in dogs, to assess correlation between the AC-cTnI-HS and a previous ADVIA Centaur TnI-Ultra (AC-cTnI-U) assay, to assess cTnI sample storage stability, and to clinically evaluate the AC-cTnI-HS assay in healthy dogs and dogs with cardiac disease. Canine serum samples were used for analytical validation. Intra- and inter-assay variability, dilutional parallelism, and spiking recovery were assessed. Samples from 196 client-owned dogs were evaluated (healthy dogs (n = 39) or dogs with congenital heart disease (n = 54), myxomatous mitral valve disease (n = 68), dilated cardiomyopathy (n = 15), or myocarditis (n = 20)). Inter- and intra-assay coefficient of variation (%CV) was between 2.8–41.4% and 3.8–30.2%, respectively, with pools with concentrations >20 pg/mL all having %CVs <10%. The observed to expected ratios for dilutional parallelism and spiking recovery experiments ranged between 92.3 and 266.7.0% and 84.3 and 108%, respectively. A strong correlation between the AC-cTnI-HS and AC-cTnI-U assays was observed (Spearman’s ρ = 0.927), though a proportional bias existed, with AC-cTnI-HS assay concentrations being proportionally lower than AC-cTnI-U assay concentrations. Serum samples stored at -80°C had stable cTnI measurements for up to 2.7 years and after a single freeze-thaw cycle. Healthy dogs and dogs with congenital heart disease had significantly lower cTnI concentrations than dogs in the other three groups. The AC-cTnI-HS assay precisely, reproducibly, and accurately measures cTnI concentrations in dog serum with cTnI concentrations >20 pg/mL. Public Library of Science 2023-07-18 /pmc/articles/PMC10353792/ /pubmed/37463140 http://dx.doi.org/10.1371/journal.pone.0288801 Text en © 2023 Wesselowski et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wesselowski, Sonya
Lidbury, Jonathan
Saunders, Ashley B.
Gordon, Sonya G.
Suchodolski, Jan S.
Steiner, Joerg M.
Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay
title Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay
title_full Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay
title_fullStr Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay
title_full_unstemmed Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay
title_short Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay
title_sort analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin i immunoassay for use in dogs, with comparison to a previous ultrasensitive assay
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353792/
https://www.ncbi.nlm.nih.gov/pubmed/37463140
http://dx.doi.org/10.1371/journal.pone.0288801
work_keys_str_mv AT wesselowskisonya analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay
AT lidburyjonathan analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay
AT saundersashleyb analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay
AT gordonsonyag analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay
AT suchodolskijans analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay
AT steinerjoergm analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay